A randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2018-10, Vol.29, p.viii596-viii596 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | viii596 |
|---|---|
| container_issue | |
| container_start_page | viii596 |
| container_title | Annals of oncology |
| container_volume | 29 |
| creator | Pujol, J.-L. Greillier, L. Audigier Valette, C. Moro-Sibilot, D. Uwer, L. Hureaux, J. Thiberville, L. Carmier, D. Madelaine, J. Otto, J. Gounant, V. Merle, P. Mourlanette, P. Molinier, O. Renault, P.A. Mazieres, J. Antoine, M. Langlais, A. Morin, F. Souquet, P.-J. |
| description | |
| doi_str_mv | 10.1093/annonc/mdy298 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdy298</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419500497</els_id><sourcerecordid>32137586</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2628-ca153aaa4db67471b9d9124992f98304181c1991a65e1f004dcc7cb8d9d890013</originalsourceid><addsrcrecordid>eNp1kc9u1DAQhy0EokvhyBXNC5jacf6Z27K0EGlREdpeeolm7QlrlNiRnS1aTrwDT8Pr8CSkCuXGxSNZ33wa_X6MvZTitRRaXaD3wZuLwZ4yXT9iK1mUmtcil4_ZSuhM8apQ-Rl7ltJXIUSpM_2UnalMqqqoyxX7tYaI3obBfScLs4qbMIwYcXJ3BOMBE0HTQJqO9gShA_ST-_3j56d3fCthvbu8vd42tzcf128hRDAHGsJ0oIjjCTBBIhO85b3zBA_fzsM4y8lPCb656QBpwL4HQ_PTH_0XMOgNxTfwmdKxn6EuhuF-G5qrzY7LUiiYosP-OXvSYZ_oxd95zm6uLnebD3x7_b7ZrLfcZGVWc4OyUIiY231Z5ZXca6tllmuddbpWc061NFJriWVBshMit8ZUZl9bbWsthFTnjC9eE0NKkbp2jG7AeGqlaO8raJcK2qWCmX-18ONxP5D9Rz9kPgPVAtB89Z2j2CYz52HIukhmam1w_1H_AQbVmZU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Pujol, J.-L. ; Greillier, L. ; Audigier Valette, C. ; Moro-Sibilot, D. ; Uwer, L. ; Hureaux, J. ; Thiberville, L. ; Carmier, D. ; Madelaine, J. ; Otto, J. ; Gounant, V. ; Merle, P. ; Mourlanette, P. ; Molinier, O. ; Renault, P.A. ; Mazieres, J. ; Antoine, M. ; Langlais, A. ; Morin, F. ; Souquet, P.-J.</creator><creatorcontrib>Pujol, J.-L. ; Greillier, L. ; Audigier Valette, C. ; Moro-Sibilot, D. ; Uwer, L. ; Hureaux, J. ; Thiberville, L. ; Carmier, D. ; Madelaine, J. ; Otto, J. ; Gounant, V. ; Merle, P. ; Mourlanette, P. ; Molinier, O. ; Renault, P.A. ; Mazieres, J. ; Antoine, M. ; Langlais, A. ; Morin, F. ; Souquet, P.-J.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdy298</identifier><identifier>PMID: 32137586</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><ispartof>Annals of oncology, 2018-10, Vol.29, p.viii596-viii596</ispartof><rights>2018 THE AUTHORS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2628-ca153aaa4db67471b9d9124992f98304181c1991a65e1f004dcc7cb8d9d890013</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32137586$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pujol, J.-L.</creatorcontrib><creatorcontrib>Greillier, L.</creatorcontrib><creatorcontrib>Audigier Valette, C.</creatorcontrib><creatorcontrib>Moro-Sibilot, D.</creatorcontrib><creatorcontrib>Uwer, L.</creatorcontrib><creatorcontrib>Hureaux, J.</creatorcontrib><creatorcontrib>Thiberville, L.</creatorcontrib><creatorcontrib>Carmier, D.</creatorcontrib><creatorcontrib>Madelaine, J.</creatorcontrib><creatorcontrib>Otto, J.</creatorcontrib><creatorcontrib>Gounant, V.</creatorcontrib><creatorcontrib>Merle, P.</creatorcontrib><creatorcontrib>Mourlanette, P.</creatorcontrib><creatorcontrib>Molinier, O.</creatorcontrib><creatorcontrib>Renault, P.A.</creatorcontrib><creatorcontrib>Mazieres, J.</creatorcontrib><creatorcontrib>Antoine, M.</creatorcontrib><creatorcontrib>Langlais, A.</creatorcontrib><creatorcontrib>Morin, F.</creatorcontrib><creatorcontrib>Souquet, P.-J.</creatorcontrib><title>A randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kc9u1DAQhy0EokvhyBXNC5jacf6Z27K0EGlREdpeeolm7QlrlNiRnS1aTrwDT8Pr8CSkCuXGxSNZ33wa_X6MvZTitRRaXaD3wZuLwZ4yXT9iK1mUmtcil4_ZSuhM8apQ-Rl7ltJXIUSpM_2UnalMqqqoyxX7tYaI3obBfScLs4qbMIwYcXJ3BOMBE0HTQJqO9gShA_ST-_3j56d3fCthvbu8vd42tzcf128hRDAHGsJ0oIjjCTBBIhO85b3zBA_fzsM4y8lPCb656QBpwL4HQ_PTH_0XMOgNxTfwmdKxn6EuhuF-G5qrzY7LUiiYosP-OXvSYZ_oxd95zm6uLnebD3x7_b7ZrLfcZGVWc4OyUIiY231Z5ZXca6tllmuddbpWc061NFJriWVBshMit8ZUZl9bbWsthFTnjC9eE0NKkbp2jG7AeGqlaO8raJcK2qWCmX-18ONxP5D9Rz9kPgPVAtB89Z2j2CYz52HIukhmam1w_1H_AQbVmZU</recordid><startdate>201810</startdate><enddate>201810</enddate><creator>Pujol, J.-L.</creator><creator>Greillier, L.</creator><creator>Audigier Valette, C.</creator><creator>Moro-Sibilot, D.</creator><creator>Uwer, L.</creator><creator>Hureaux, J.</creator><creator>Thiberville, L.</creator><creator>Carmier, D.</creator><creator>Madelaine, J.</creator><creator>Otto, J.</creator><creator>Gounant, V.</creator><creator>Merle, P.</creator><creator>Mourlanette, P.</creator><creator>Molinier, O.</creator><creator>Renault, P.A.</creator><creator>Mazieres, J.</creator><creator>Antoine, M.</creator><creator>Langlais, A.</creator><creator>Morin, F.</creator><creator>Souquet, P.-J.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201810</creationdate><title>A randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial</title><author>Pujol, J.-L. ; Greillier, L. ; Audigier Valette, C. ; Moro-Sibilot, D. ; Uwer, L. ; Hureaux, J. ; Thiberville, L. ; Carmier, D. ; Madelaine, J. ; Otto, J. ; Gounant, V. ; Merle, P. ; Mourlanette, P. ; Molinier, O. ; Renault, P.A. ; Mazieres, J. ; Antoine, M. ; Langlais, A. ; Morin, F. ; Souquet, P.-J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2628-ca153aaa4db67471b9d9124992f98304181c1991a65e1f004dcc7cb8d9d890013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pujol, J.-L.</creatorcontrib><creatorcontrib>Greillier, L.</creatorcontrib><creatorcontrib>Audigier Valette, C.</creatorcontrib><creatorcontrib>Moro-Sibilot, D.</creatorcontrib><creatorcontrib>Uwer, L.</creatorcontrib><creatorcontrib>Hureaux, J.</creatorcontrib><creatorcontrib>Thiberville, L.</creatorcontrib><creatorcontrib>Carmier, D.</creatorcontrib><creatorcontrib>Madelaine, J.</creatorcontrib><creatorcontrib>Otto, J.</creatorcontrib><creatorcontrib>Gounant, V.</creatorcontrib><creatorcontrib>Merle, P.</creatorcontrib><creatorcontrib>Mourlanette, P.</creatorcontrib><creatorcontrib>Molinier, O.</creatorcontrib><creatorcontrib>Renault, P.A.</creatorcontrib><creatorcontrib>Mazieres, J.</creatorcontrib><creatorcontrib>Antoine, M.</creatorcontrib><creatorcontrib>Langlais, A.</creatorcontrib><creatorcontrib>Morin, F.</creatorcontrib><creatorcontrib>Souquet, P.-J.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pujol, J.-L.</au><au>Greillier, L.</au><au>Audigier Valette, C.</au><au>Moro-Sibilot, D.</au><au>Uwer, L.</au><au>Hureaux, J.</au><au>Thiberville, L.</au><au>Carmier, D.</au><au>Madelaine, J.</au><au>Otto, J.</au><au>Gounant, V.</au><au>Merle, P.</au><au>Mourlanette, P.</au><au>Molinier, O.</au><au>Renault, P.A.</au><au>Mazieres, J.</au><au>Antoine, M.</au><au>Langlais, A.</au><au>Morin, F.</au><au>Souquet, P.-J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2018-10</date><risdate>2018</risdate><volume>29</volume><spage>viii596</spage><epage>viii596</epage><pages>viii596-viii596</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><cop>England</cop><pub>Elsevier Ltd</pub><pmid>32137586</pmid><doi>10.1093/annonc/mdy298</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2018-10, Vol.29, p.viii596-viii596 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdy298 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | A randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T03%3A41%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20randomized%20non-comparative%20phase%20II%20study%20of%20anti%E2%80%93PD-L1%20ATEZOLIZUMAB%20or%20chemotherapy%20as%20second-line%20therapy%20in%20patients%20with%20small%20cell%20lung%20cancer:%20Results%20from%20the%20IFCT-1603%20trial&rft.jtitle=Annals%20of%20oncology&rft.au=Pujol,%20J.-L.&rft.date=2018-10&rft.volume=29&rft.spage=viii596&rft.epage=viii596&rft.pages=viii596-viii596&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdy298&rft_dat=%3Cpubmed_cross%3E32137586%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32137586&rft_els_id=S0923753419500497&rfr_iscdi=true |